Investor Presentation Q1-Q3 2020

22 Investor presentation First nine months of 2020 Novo Nordisk has leading positions in diabetes, obesity and haemophilia Diabetes care DKK billion 700 600 500 400 300 200 CAGR¹ value: 12.0% 100 0 Aug 2015 Obesity care DKK billion #1 50% 12 10 40% 8 30% Haemophilia DKK billion #1 80% 80 60% 60 00 40% 40 40 Novo NordiskⓇ (#2 50% 40% 30% 20% 20% 4 20% 20 10% 2 CAGR² value: 10.1% CAGR³ value: 2.0% 10% 0% 0 0% 0 0% Aug 2020 Aug Aug FY FY 2018 Market value 2020 2015 Market value 2019 -NN value market share -NN value market share Global market position Global market position Market value NN value market share Global market position 1 CAGR for 5-year period; 2 CAGR for 2-year period; 3 CAGR for 5-year period; Note: Annual sales figures for haemophilia A, B and bypassing agents segment. Recombinant and plasma derived products Source: Company reports, IQVIA MAT, Aug 2020 NN: Novo Nordisk

View entire presentation